Developer docs
API playgroundTry for free, no card

Search company profiles

Galecto

Full company profile

uuid0000ak5

Namestring
Galecto
Legal namestring
Galecto, Inc.
Websiteurl
galecto.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biopharmaceutical company developing therapeutics for hematological cancers, headquartered in Boston, Massachusetts, and incorporated in Delaware with a pending redomestication to the Cayman Islands. The company was founded in 2011 and operates a portfolio anchored by two investigational assets: DMR-001, a monoclonal antibody targeting mutant calreticulin (mutCALR) for myeloproliferative neoplasms including essential thrombocythemia and myelofibrosis, which was acquired in November 2025 through the purchase of Damora Therapeutics and uses a proprietary half-life extension technology to enable subcutaneous administration; and GB3226, a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML). Galecto plans to file a regulatory submission for DMR-001 in mid-2026 to initiate a global Phase 1/1b trial, with two clinical proof-of-concept datasets expected beginning in mid-2027.

Galecto is pre-revenue and has no commercialized products, generating no product sales, royalties, or collaboration revenue as of the latest disclosures. Its business model is conventional clinical-stage biotech: advance candidates through IND-enabling work and clinical trials with the intent to either commercialize independently in rare-disease indications or partner for larger indications, monetizing ultimately through drug sales rather than software, services, or licensing fees today. The company's go-to-market relies on scientific communication channels — primarily presentations at major hematology/oncology conferences such as ASH — and investor relations, with planned post-approval distribution through specialty and hospital pharmacies typical for rare-disease therapeutics.

The company raised approximately $284.9 million in a November 2025 oversubscribed private placement concurrent with the Damora acquisition, followed by a $275 million underwritten public offering in February 2026, providing stated runway into 2029. Capital structure and shareholder base include specialist biotech investors (Fairmount, RA Capital, Perceptive Advisors, Janus Henderson, Viking Global, Wellington, BB Biotech, Forbion, OrbiMed, Novo Holdings), and Leerink Partners initiated coverage with an Outperform rating and a $46 price target, modeling peak sales of $3.3 billion for DMR-001 in myelofibrosis and $3.0 billion in essential thrombocythemia. Leadership transitioned in early 2026, with founder/CEO Hans T. Schambye departing and former Blueprint Medicines executive Sherwin Sattarzadeh appointed interim principal executive officer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, monoclonal antibody therapy, hematological cancer therapeutics, myeloproliferative neoplasm drugs, fibrosis therapeutics
Industry2 codes
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Hematological Cancer Therapeutics
No data
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Galecto is a clinical-stage biopharmaceutical company developing novel disease-modifying treatments for hematological cancers. Its lead candidate DMR-001 is an investigational monoclonal antibody therapy targeting mutant calreticulin-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), while GB3226 is a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia. The company does not yet have commercialized products and intends to commercialize these candidates through specialty pharmaceutical distribution channels upon regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Approximately 10-fold increase in potency against Type 2 mutant cells compared to reference antibody
+3 more records
Product overview1 text field

Galecto is a clinical-stage biopharmaceutical company developing treatments for hematological cancers. The company operates a portfolio approach with two key investigational candidates: DMR-001 (acquired through Damora Therapeutics), a monoclonal antibody therapy targeting mutant calreticulin-driven myeloproliferative neoplasms, and GB3226, a dual inhibitor for acute myeloid leukemia.

Product and service2 records
1DMR-001
CategoryInvestigational monoclonal antibody therapeutic
Description

An investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR) with best-in-class potential for treating myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). Designed to exclusively bind mutCALR with exquisite selectivity, potency, and extended half-life, enabling convenient infrequent subcutaneous dosing via autoinjector. Preclinical studies demonstrated approximately 10-fold increase in potency against Type 2 mutant cells and approximately 5-fold increase in half-life versus reference antibody.

2GB3226
CategoryInvestigational small molecule inhibitor therapeutic
Description

A dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML). Novel mechanism targeting both ENL-YEATS and FLT3 pathways, demonstrating potent preclinical activity and promising efficacy in AML models across various genotypes. Designed for the treatment of acute myeloid leukemia patients across heterogeneous genetic subsets.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-10
Description

Galecto acquired Damora Therapeutics, a biotech company focused on therapies for mutant calreticulin-driven myeloproliferative neoplasms. The acquisition enhances Galecto's pipeline for hematological cancers and was supported by a private placement of approximately $285 million.

Strategic tierCoreTypeTechnology or Integration
Description

Galecto issued a warrant to Paragon Therapeutics' affiliate Paramora Holding LLC for the purchase of up to 628,302 shares at $23.01 per share, as part of an antibody discovery and option agreement. This partnership supports Galecto's antibody discovery programs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing bezuclastinib and other kinase inhibitors for systemic mastocytosis and mutant KIT-driven myeloid neoplasms, directly competing with Galecto in the MPN / hematologic malignancy space with similar stage and modality profile.

TypeDirect peer
Description

Clinical-stage rare hematology biotech developing therapeutics for hematologic disorders including myelofibrosis and other bone marrow failure diseases, comparable in size, stage, and therapeutic area focus to Galecto's mutCALR-driven MPN franchise.

TypeDirect peer
Description

Commercial-stage rare hematology/oncology company with AYVAKIT (avapritinib) in systemic mastocytosis and GAVRETO in lung cancer. Highly comparable for its MPN-adjacent positioning, leadership pedigree (Galecto's COO and CMO are alumni), and rare-disease strategy.

4Bristol-Myers Squibb
TypeBroad incumbent
Description

Major pharma with an established MPN franchise including Reblozyl (luspatercept) and Inrebic (fedratinib) for myelofibrosis. Represents the incumbent standard of care and likely strategic acquirer for next-generation MPN assets like DMR-001.

TypeBroad incumbent
Description

Developer and marketer of Jakafi (ruxolitinib), the leading JAK inhibitor for myelofibrosis and polycythemia vera. Sets the commercial benchmark against which any new MPN therapy, including DMR-001, will be measured.

TypeBroad incumbent
Description

Marketer of Ojjaara (momelotinib) for myelofibrosis patients with anemia, acquired through Sierra Oncology. Directly competes with Galecto's potential myelofibrosis positioning of DMR-001.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics targeting TGF-beta superfamily for hematologic disorders including MDS and MPNs. Comparable in stage and rare hematology focus, though with a different mechanistic approach.

TypeEmerging player
Description

Recently launched Rytelo (imetelstat) for transfusion-dependent MDS, with ongoing development in myelofibrosis. Comparable as a late clinical / early commercial rare hematology company pursuing MPN indications.

TypeBroad incumbent
Description

Acquired CTI BioPharma and markets Vonjo (pacritinib) for myelofibrosis. A key established player in the MPN space and a credible strategic acquirer profile similar to the types of companies Galecto could eventually partner with.

TypeBroad incumbent
Description

Major oncology player with a hematology presence and historically active in MPN commercial landscapes (e.g., Imbruvica, Venclexta). Represents a likely large-pharma counterparty for partnership or acquisition of a focused MPN asset like DMR-001.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors33 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galecto

Hematological Cancer Therapeuticsgalecto.com

What Galecto does

Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biopharmaceutical company developing therapeutics for hematological cancers, headquartered in Boston, Massachusetts, and incorporated in Delaware with a pending redomestication to the Cayman Islands. The company was founded in 2011 and operates a portfolio anchored by two investigational assets: DMR-001, a monoclonal antibody targeting mutant calreticulin (mutCALR) for myeloproliferative neoplasms including essential thrombocythemia and myelofibrosis, which was acquired in November 2025 through the purchase of Damora Therapeutics and uses a proprietary half-life extension technology to enable subcutaneous administration; and GB3226, a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML). Galecto plans to file a regulatory submission for DMR-001 in mid-2026 to initiate a global Phase 1/1b trial, with two clinical proof-of-concept datasets expected beginning in mid-2027.

Galecto is pre-revenue and has no commercialized products, generating no product sales, royalties, or collaboration revenue as of the latest disclosures. Its business model is conventional clinical-stage biotech: advance candidates through IND-enabling work and clinical trials with the intent to either commercialize independently in rare-disease indications or partner for larger indications, monetizing ultimately through drug sales rather than software, services, or licensing fees today. The company's go-to-market relies on scientific communication channels — primarily presentations at major hematology/oncology conferences such as ASH — and investor relations, with planned post-approval distribution through specialty and hospital pharmacies typical for rare-disease therapeutics.

The company raised approximately $284.9 million in a November 2025 oversubscribed private placement concurrent with the Damora acquisition, followed by a $275 million underwritten public offering in February 2026, providing stated runway into 2029. Capital structure and shareholder base include specialist biotech investors (Fairmount, RA Capital, Perceptive Advisors, Janus Henderson, Viking Global, Wellington, BB Biotech, Forbion, OrbiMed, Novo Holdings), and Leerink Partners initiated coverage with an Outperform rating and a $46 price target, modeling peak sales of $3.3 billion for DMR-001 in myelofibrosis and $3.0 billion in essential thrombocythemia. Leadership transitioned in early 2026, with founder/CEO Hans T. Schambye departing and former Blueprint Medicines executive Sherwin Sattarzadeh appointed interim principal executive officer.

Galecto firmographics

Firmographics
Name
Galecto
Legal name
Galecto, Inc.
Website
https://galecto.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Galecto industry classification

Industry
Product category
Hematological Cancer Therapeutics
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)

Keywords

  • Clinical-stage biopharmaceutical
  • Monoclonal antibody therapy
  • Hematological cancer therapeutics
  • Myeloproliferative neoplasm drugs
  • Fibrosis therapeutics

Where Galecto is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Galecto business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Marketing channels1 record

Galecto product offering

Product offering

Core offering

Galecto is a clinical-stage biopharmaceutical company developing novel disease-modifying treatments for hematological cancers. Its lead candidate DMR-001 is an investigational monoclonal antibody therapy targeting mutant calreticulin-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), while GB3226 is a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia. The company does not yet have commercialized products and intends to commercialize these candidates through specialty pharmaceutical distribution channels upon regulatory approval.

Product overview

Galecto is a clinical-stage biopharmaceutical company developing treatments for hematological cancers. The company operates a portfolio approach with two key investigational candidates: DMR-001 (acquired through Damora Therapeutics), a monoclonal antibody therapy targeting mutant calreticulin-driven myeloproliferative neoplasms, and GB3226, a dual inhibitor for acute myeloid leukemia.

Differentiator

Problem solved

Functional benefit

Products and services

  • DMR-001 An investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR) with best-in-class potential for treating myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). Designed to exclusively bind mutCALR with exquisite selectivity, potency, and extended half-life, enabling convenient infrequent subcutaneous dosing via autoinjector. Preclinical studies demonstrated approximately 10-fold increase in potency against Type 2 mutant cells and approximately 5-fold increase in half-life versus reference antibody.
  • GB3226 A dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML). Novel mechanism targeting both ENL-YEATS and FLT3 pathways, demonstrating potent preclinical activity and promising efficacy in AML models across various genotypes. Designed for the treatment of acute myeloid leukemia patients across heterogeneous genetic subsets.

Quantifiable outcome

  • Approximately 10-fold increase in potency against Type 2 mutant cells compared to reference antibody
  • +3 more outcomes

Companies that use Galecto

Customer profile

Segments2 records

Ideal customer profiles2 records

Galecto technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Galecto partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Damora TherapeuticscoreStrategic or Co-development Partner · 10 November 2025Galecto acquired Damora Therapeutics, a biotech company focused on therapies for mutant calreticulin-driven myeloproliferative neoplasms. The acquisition enhances Galecto's pipeline for hematological cancers and was supported by a private placement of approximately $285 million.
  • Paragon TherapeuticscoreTechnology or IntegrationGalecto issued a warrant to Paragon Therapeutics' affiliate Paramora Holding LLC for the purchase of up to 628,302 shares at $23.01 per share, as part of an antibody discovery and option agreement. This partnership supports Galecto's antibody discovery programs.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Galecto competitors and assessment

Company assessment

Direct peers

  • Cogent Biosciences: Clinical-stage biotech developing bezuclastinib and other kinase inhibitors for systemic mastocytosis and mutant KIT-driven myeloid neoplasms, directly competing with Galecto in the MPN / hematologic malignancy space with similar stage and modality profile.
  • Disc Medicine: Clinical-stage rare hematology biotech developing therapeutics for hematologic disorders including myelofibrosis and other bone marrow failure diseases, comparable in size, stage, and therapeutic area focus to Galecto's mutCALR-driven MPN franchise.
  • Blueprint Medicines: Commercial-stage rare hematology/oncology company with AYVAKIT (avapritinib) in systemic mastocytosis and GAVRETO in lung cancer. Highly comparable for its MPN-adjacent positioning, leadership pedigree (Galecto's COO and CMO are alumni), and rare-disease strategy.

Broad incumbents

  • Bristol-Myers Squibb: Major pharma with an established MPN franchise including Reblozyl (luspatercept) and Inrebic (fedratinib) for myelofibrosis. Represents the incumbent standard of care and likely strategic acquirer for next-generation MPN assets like DMR-001.
  • Incyte: Developer and marketer of Jakafi (ruxolitinib), the leading JAK inhibitor for myelofibrosis and polycythemia vera. Sets the commercial benchmark against which any new MPN therapy, including DMR-001, will be measured.
  • GSK: Marketer of Ojjaara (momelotinib) for myelofibrosis patients with anemia, acquired through Sierra Oncology. Directly competes with Galecto's potential myelofibrosis positioning of DMR-001.
  • Sobi (Swedish Orphan Biovitrum): Acquired CTI BioPharma and markets Vonjo (pacritinib) for myelofibrosis. A key established player in the MPN space and a credible strategic acquirer profile similar to the types of companies Galecto could eventually partner with.
  • AbbVie: Major oncology player with a hematology presence and historically active in MPN commercial landscapes (e.g., Imbruvica, Venclexta). Represents a likely large-pharma counterparty for partnership or acquisition of a focused MPN asset like DMR-001.

Emerging players

  • Keros Therapeutics: Clinical-stage biotech developing therapeutics targeting TGF-beta superfamily for hematologic disorders including MDS and MPNs. Comparable in stage and rare hematology focus, though with a different mechanistic approach.
  • Geron Corporation: Recently launched Rytelo (imetelstat) for transfusion-dependent MDS, with ongoing development in myelofibrosis. Comparable as a late clinical / early commercial rare hematology company pursuing MPN indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Galecto financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galecto leadership team

Management profile

Number of profiles

Profiles10 records

Galecto subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Galecto funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galecto M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galecto

What does Galecto do?

Galecto is a clinical-stage biopharmaceutical company developing novel disease-modifying treatments for hematological cancers. Its lead candidate DMR-001 is an investigational monoclonal antibody therapy targeting mutant calreticulin-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), while GB3226 is a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia. The company does not yet have commercialized products and intends to commercialize these candidates through specialty pharmaceutical distribution channels upon regulatory approval.

Is Galecto a public or private company?

Galecto is a public company. It is classified as public and is currently operating.

When was Galecto founded?

Galecto was founded in 2011. It employs 1 to 10 people.

Where is Galecto based?

Galecto is headquartered in Copenhagen, Denmark, in the Europe region.

Who are Galecto's main competitors?

Direct peers on record are Cogent Biosciences, Disc Medicine and Blueprint Medicines. Broad incumbents are Bristol-Myers Squibb, Incyte, GSK, Sobi (Swedish Orphan Biovitrum) and AbbVie. Emerging players are Keros Therapeutics and Geron Corporation.

Does Galecto have an API?

No public API is recorded for Galecto.

What industry is Galecto in?

Galecto's product category is Hematological Cancer Therapeutics. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaGalecto reports Q2 results (DMRA:NASDAQ)Galecto (DMRA) reported a net loss of $31.2 million for Q2 2026, significantly higher than the $3.4 million loss reported in Q2 2025. Other income increased to $4.1 million due to increased interest income from recent financings. The company holds approximately $540.5 million in cash and expects to fund operations into the second half of 2029, with net cash used in operating activities of $21.9 million for the quarter.The Pharma LetterJennifer Jarrett joins Damora as CEODamora Therapeutics appointed Jennifer Jarrett as president and CEO, with her also serving on the board. She brings nearly three decades of experience in corporate strategy, finance, investor relations, drug development, and organizational leadership.Investing.comGalecto rebrands as Damora Therapeutics, begins Nasdaq trading By Investing.comGalecto Inc. has rebranded as Damora Therapeutics Inc. and will begin trading on Nasdaq under the symbol DMRA following the completion of its acquisition of privately held Damora and concurrent private investment of approximately $285 million in November 2025. The company also completed a public offering in February 2026 raising $316 million in gross proceeds, reporting cash and cash equivalents of approximately $535 million as of February 28, 2026. The funding is expected to support Phase 3 development of DMR-001, a monoclonal antibody therapy targeting mutant calreticulin, with regulatory submission planned for mid-2026 and proof-of-concept data expected beginning mid-2027.Investing.comUBS initiates Galecto stock with buy rating on blood disorder drug By Investing.comUBS initiated coverage on Galecto with a buy rating and a $45 price target, highlighting the company's blood disorder drug development. Galecto acquired DMR-001 through a reverse merger and plans to leverage it for treating essential thrombocythemia and myelofibrosis.Investing.comGalecto shares fall after $275 million equity raise at discount By Investing.comGalecto's shares declined following a $275 million equity financing at a discount. The article primarily reports on the company's stock performance and capital raising activities.Investing.comGalecto prices $275 million public offering at $19 per share By Investing.comGalecto, Inc., a Boston-based biopharmaceutical company developing treatments for hematological cancers, priced an underwritten public offering of 14,473,685 shares of common stock at $19.00 per share, representing a discount to its market price of $21.52 and expected to raise approximately $275 million in gross proceeds before fees, with closing anticipated on or about February 12. The company, which is not currently profitable, also disclosed recent leadership changes including CEO Hans T. Schambye's resignation from the board and his position. Leerink Partners, which is serving as a joint book-running manager on the offering, has separately initiated coverage on Galecto with an Outperform rating and a $46.00 price target.GlobeNewswireGalecto Announces Pricing of $275 Million Underwritten Public OfferingGalecto, Inc., a clinical-stage biopharmaceutical company focused on blood cancers, has priced an underwritten public offering of 14,473,685 shares of common stock at $19.00 per share, expected to raise approximately $275 million in gross proceeds before underwriting discounts and expenses. The offering is expected to close on or about February 12, 2026, subject to customary closing conditions, with Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities serving as joint book-running managers. The company has granted the underwriters a 30-day option to purchase up to an additional 2,171,052 shares at the public offering price.Stock TitanGalecto prices $275M stock offering at $19Galecto, Inc., a clinical-stage biopharmaceutical company focused on blood cancer therapeutics, priced an underwritten public offering of 14,473,685 shares of common stock at $19.00 per share, raising approximately $275 million in gross proceeds. The offering, expected to close on or about February 12, 2026, includes a 30-day option for underwriters to purchase an additional 2,171,052 shares. Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are serving as joint book-running managers for the offering.BioSpaceGalecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockGalecto, Inc., a clinical-stage biopharmaceutical company focused on hematological cancer therapeutics, announced a proposed underwritten public offering of common stock and Series C non-voting convertible preferred stock, with Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities acting as joint book-running managers. The company intends to use proceeds for preclinical studies, clinical trials, manufacturing, research and development, and general corporate purposes. The offering is subject to market conditions with no assurance of completion or final terms.